Alzheimer's Association International Conference

Alzheimer's Association International Conference

Perspective from Christopher Weber, PhD
Source:

Press Release

Disclosures: Healio Neurology could not confirm relevant financial disclosures for Hill and Massett at the time of publication.
July 30, 2021
2 min read
Save

New tool aims to increase enrollment in trials for Alzheimer's disease, other dementias

Perspective from Christopher Weber, PhD
Source:

Press Release

Disclosures: Healio Neurology could not confirm relevant financial disclosures for Hill and Massett at the time of publication.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The online tool Outreach Pro was launched at the Alzheimer’s Association International Conference to raise awareness of clinical trials for Alzheimer’s disease and other dementias, specifically in “traditionally underrepresented communities.”

In addition to the launch of Outreach Pro, additional findings related to improving diversity in AD and dementia clinical trials included the following:

Reference: Alzheimer’s Association. Addressing diversity in Alzheimer’s clinical trials. Available at: https://www.alz.org/aaic/releases_2021/clinical-trial-diversity.asp. Accessed July 30, 2021.

People are most inclined to participate in a clinical trial if they are invited to do so (85%), are interested in contributing to the aims of the research (83%) or have a family member impacted by the disease (74%);

Black, Latino and American Indian respondents are considerably more likely to participate if someone of the same race asks them and are more concerned than white people about the trial’s impact on work and family responsibilities and the availability of transportation and childcare; and

Exclusion criteria frequently used in AD clinical trials have the potential to disproportionately impact Black and Hispanic/Latino participants, which may have a role in their decreased enrollment in research.

“There is a well-recognized need for diversity in clinical trial populations to ensure diagnostics and treatments are safe and effective for everyone,” Carl V. Hill, MPH, PhD, chief diversity, equity and inclusion officer of the Alzheimer’s Association, said in a press release. “It’s imperative that the [AD] community is aware of the impact of historical racism and also the current racial discrimination in health care that presents obstacles for inclusive participation in [AD] trials. ... Just as important, it is critical that we evaluate strategies that have been shown to be effective when recruiting historically underrepresented individuals and communities in these vital [AD] research studies.”

The National Institute on Aging launched Outreach Pro to raise awareness of AD and dementia clinical trials and to increase participation, according to the press release. The tool enables a variety of health care professionals — including researchers, clinicians, clinical trial administrators and staff — to create and customize outreach materials such as websites, handouts, videos and social media posts with a focus on reaching communities that are usually underrepresented.

The templates included in Outreach Pro allow researchers and clinicians to create materials for outreach from templates that are meant to educate people about AD and dementia; increase overall awareness of AD clinical trials; and offer information about a specific clinical study in AD or dementia that is openly recruiting patients, according to the press release. The templates can be customized through a main library that includes messages, headlines, photos and text that were “extensively tested,” including in groups that represented “diverse and underserved populations.”

Materials created specifically for Black and Hispanic/Latino patients are available in the current Outreach Pro library, according to the press release, and are available in English as well as Spanish. These materials included at launch are leave-behind brochures and fact sheets, online libraries of photos/images, videos, social media posts and motion graphics, according to the press release. Researchers have begun working to add materials for Asian Americans and Pacific Islanders in multiple languages by fall 2021 and for American Indian and Alaska Natives groups by 2022.

“It is critical that clinical trials have appropriate representation to ensure that we have a complete understanding of how well different therapies or approaches to dementia care work in different populations,” Holly Massett, PhD, senior advisor on clinical research recruitment and engagement at the National Institute on Aging, who oversees the implementation of the national strategy, said in the press release. “Outreach Pro was designed to provide well-tested and culturally appropriate outreach materials that resonate with diverse populations and encourage them to participate in clinical trials.”

Reference:

Alzheimer’s Association. Addressing diversity in Alzheimer’s clinical trials. Available at: https://www.alz.org/aaic/releases_2021/clinical-trial-diversity.asp. Accessed July 30, 2021.